Elisa Agostinetto , Daniel Eiger , Matteo Lambertini , Marcello Ceppi , Marco Bruzzone , Noam Ponde , Chris Plummer , Ahmad Hussein Awada , Martine Piccart-Gebhart , Evandro de Azambuja
Introduction: ICI can cause potentially life-threatening adverse events (AE) and their risk of cardiotoxicity has been poorly investigated. It is also unknown whether ICI combinations increases cardiotoxicity compared to single ICI. We aimed to assess the cardiotoxicity rate of ICI compared to other cancer treatments (primary objective) and of dual-agent ICI (immunotherapy combinations) compared to single-agent ICI (secondary objective).
Rafael Caparica , Elisa Agostinetto , Lucas Vian , Marco Bruzzone , Marcello Ceppi , Noam Ponde , Matteo Lambertini , Evandro de Azambuja
Introduction/aim: The combination of CDK4-6i and endocrine therapy (ET) is standard-of- care for pts with HR+/HER2- advanced breast cancer. However, studies evaluating adjuvant CDK4-6i provided contradictory results thus far. We conducted a systematic review and meta-analysis to assess if the addition of CDK4-6i to adjuvant ET impacts on survival’s outcomes and safety of pts with HR+/HER2- EBC.
